About Cleveland BioLabs (NASDAQ: CBLI) Stock
Statera Biopharma, Inc. is a Delaware-based corporation. Pharmaceutical preparations are Statera Biopharma, Inc.’s primary industry. Their fiscal year, as it relates to financial reporting, concludes on December 31. This page contains information about Statera Biopharma, Inc.’s SEC registration as well as a list of all the documents it has filed, including the S-1, Prospectus, Current Reports, 8-K, 10K, and Annual Reports.
A biopharmaceutical company is Cleveland BioLabs Inc. The business is creating new strategies to boost the immune system and address pressing medical issues.
Applications for its patented platform of Toll-like immune receptor activators include immuno-oncology and the reduction of radiation harm. Entolimod, an immunostimulatory drug created as an anti-radiation measure and immunotherapy for oncology and other applications, is its flagship product candidate.
Entolimod is a Toll-like receptor 5 (TLR5) agonist created as an oncology medicine and radiation countermeasure to prevent death from acute radiation syndrome (ARS).
Cleveland BioLabs, Inc. (“CBLI” or the “Company”) is a cutting-edge biopharmaceutical business that creates fresh strategies to boost the immune system and take care of pressing medical issues.
Oncology and radiation safety are two fields where our patented platform of TLR activators can be used. We are passionate about creating medicines that can save lives, and we combine our demonstrated scientific expertise with our in-depth understanding of the mechanisms of action of our products.
Entolimod, our most advanced product candidate, is an immunostimulatory drug that we are developing for use in radiation oncology and other medical radiation countermeasures.
CBLI has its main office in Buffalo, New York, established in Delaware in June 2003.
A wholly owned subsidiary of CBLI, BioLab 612, LLC (“BioLab 612“), which started operations in 2012 and was decided to dissolve by the Company’s Board of Directors in September 2019, and Panacela Labs, Inc. (“Panacela“), which was established by Joint Stock Company “and us RUSNANO” (“RUSNANO“), our financial partner in the venture, in 2011 both conduct business in the United States (“U.S.“) directly and in the Russian Federation (“Russia“)
The terms “Company,” “we,” “us,” and “our,” unless otherwise specified, refer to Cleveland BioLabs, Inc. and all of its subsidiaries.
Additionally, in the financial statements that follow, the Company’s investment in Genome Protection, Inc. (hereafter referred to as “GPI“) is disclosed using the equity method of accounting.
Since the effect would have brought the Company’s equity method investment in GPI below zero, the Company has not recorded its 50% share of the losses of GPI through March 31, 2020. As of the date filed these statements were, there are no requirements to fund the Company’s share of these losses or contribute additional capital.
How to buy CBLI stock on Public
1. Create a Public Brokerage account.
Starting is simple. By downloading the Public app for iOS or Android, you can register for an account immediately on our website.
2. Invest money in your public account.
Your Public account can be fund in various ways, including by linking a bank account and making a deposit via a debit card or wire transfer.
3. Decide how much money you want to put into CBLI shares.
Go to the Explore page by navigating. Enter CBLI into the search box after that. Tap the CBLI stock when you see it in the results to bring up the purchase screen.
4. In one location, manage your investments.
Along with the rest of your stocks, ETFs, cryptos, and other assets, your recently acquired CBLI stock may be found in your portfolio.
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company. A biopharmaceutical company is Cleveland BioLabs Inc. The business is creating new strategies to boost the immune system and address pressing medical issues. How to buy CBLI stock on Public, sign-up account, Invest money, and Decide how much money you want to put into CBLI shares.
Frequently Asked Questions
Q1.What is the stock market value of CBLI?
CBLI stock’s market capitalization as of November 24, 2022, is $5.55M.
Q2.What is the CBLI stock’s 52-week high?
CBLI stock has a 52-week high of $3.49. The price of CBLI stock currently is $0, 100.00% less than its 52-week high.
Q3.When did CBLI stock reach its 52-week low?
The stock of CBLI has a 52-week low of $0.10. The price of CBLI stock currently is $0, up 100.00% from its 52-week low.
Q4.Do dividends on CBLI stock accrue?
No, the stockholders of CBLI shares do not get dividends.